As more clinical data accumulates, MAVS-targeted therapies are expected to emerge as novel strategies for managing complex immune and inflammatory diseases, which could open new avenues for MAVS-targeted immunotherapy, not only in virus-associated tumors but also in a range of inflammatory and autoimmune disorders. This evidence concerns the gene MAVS and Autoimmunity.